Second-line Antipsychotics

ApprovedSmall molecule

Second-line Antipsychotics is one of 70 small molecule programs targeting Major Depressive Disorder. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Major Depressive DisorderActive, not recruiting

SchizophreniaActive, not recruiting

Major Depressive DisorderPhase 3

Active, not recruiting

SchizophreniaApproved

Active, not recruiting

Competition

Competitive Landscape

583 competitors in Schizophrenia

#DrugCompanyPhaseTrials

Second-line Antipsychotics

DDr. Inge Winter

Approved

1 2

Celexa

AbbVie

Preclinical

4 3

Inapsine

Alnylam Pharmaceuticals

Preclinical

1 4

Depakote

AbbVie

Preclinical

—5

Comtan

Orion Corporation, Orion Pharma

Preclinical

1 6

Catapres

Boehringer Ingelheim

Preclinical

1 7

Persantine

Boehringer Ingelheim

Preclinical

1 8

Inversine

TTargacept Inc.

Preclinical

1 9

Orap

Teva

Preclinical

2 10

Vumerity

Biogen

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 3Recruiting

Major Depressive Disorder

NCT05603104

Post-ApprovalRecruiting

Schizophrenia

NCT05958875

Phase 3Recruiting

Major Depressive Disorder

NCT05973851

Clinical

Trials by Indication[1]

Major Depressive Disorder2 trials

Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure

Recruiting·—·Phase 3·NCT05603104·1,254 enrolled

The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.

Recruiting·—·Phase 3·NCT05973851·418 enrolled

Schizophrenia1 trial

The Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.

Recruiting·—·Phase 4·NCT05958875·418 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Second-line Antipsychotics. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Second-line Antipsychotics compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Second-line Antipsychotics. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Dr. Inge Winter company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: DDr. Inge Winter

Second-line Antipsychotics

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Major Depressive Disorder2 trials

Schizophrenia1 trial

References

Drug Info

Quick Facts

Related News